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To understand how extracellular vesicle (EV) subtypes differentially activate monocytes, a
series of in vitro studies were performed. We found that plasma-EVs biased monocytes
toward an M1 profile. Culturing monocytes with granulocyte-, monocyte-, and endothelialEVs induced several pro-inflammatory cytokines. By contrast, platelet-EVs induced TGF-β
and GM-CSF, and red blood cell (RBC)-EVs did not activate monocytes in vitro. The
scavenger receptor CD36 was important for binding of RBC-EVs to monocytes, while
blockade of CD36, CD163, CD206, TLR1, TLR2, and TLR4 did not affect binding of
plasma-EVs to monocytes in vitro. To identify mortality risk factors, multiple soluble
factors and EV subtypes were measured in patients’ plasma at intensive care unit
admission. Of 43 coagulation factors and cytokines measured, two were significantly
associated with mortality, tissue plasminogen activator and cystatin C. Of 14 cellular
markers quantified on EVs, 4 were early predictors of mortality, including the granulocyte
marker CD66b. In conclusion, granulocyte-EVs have potent pro-inflammatory effects on
monocytes in vitro. Furthermore, correlation of early granulocyte-EV levels with mortality
in critically ill patients provides a potential target for intervention in management of the
pro-inflammatory cascade associated with critical illness.
Keywords: extracellular vesicles, monocytes, granulocytes, exosomes, microvesicles, mortality, intensive care
unit, receptor

INTRODUCTION
Extracellular vesicles (EVs) are double membrane vesicles that can be released from virtually all
cell types under physiological and pathological conditions and may be detected in blood and other
body fluids (1, 2). The role of EVs in cell–cell communication and immunity is a new area in biology and medicine, and immunosuppressive and immunostimulatory roles have been attributed to
EVs (3–6). We previously showed that EVs from stored leukoreduced blood are heterogeneous and
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MATERIALS AND METHODS

originate from multiple cell types. We observed that monocytes
bind to and engulf EVs, and T cell response modulation by EVs
is indirect and mediated via monocyte activation (7). Red blood
cell (RBC)-EVs have been described as immunosuppressive or
immunostimulatory in separate studies (8, 9). The literature is also
conflicting on the stimulatory vs. suppressive effect of plateletEVs on monocytes and macrophages (10, 11).
Understanding how EV subtypes interact with immune
cells would better allow their manipulation in disease states,
as several mechanisms of uptake have been described for EVs.
EV surface proteins can play an important role in EV uptake, as
treatment of EVs with proteinase K decreases the uptake of EVs
by ovarian cancer cells (12). Phagocytosis, clathrin-mediated
endocytosis, caveolin-mediated endocytosis, and membrane
fusion are suggested mechanisms for EV uptake (13). It is
believed that adhesion molecules, integrins, and lectins play
a role in EV uptake (13–15). Proteoglycans such as heparin
sulfate may also play a role in EV uptake, as treatment of cells
with a heparin sulfate mimetic reduces EV uptake (16). The
role of TLRs in EV uptake has also been studied, and the data
in the literature on TLRs are conflicting (17, 18). In general,
EV uptake can involve several receptors (12, 19–24). The role
of scavenger receptors in EV uptake is not well studied, but
it has been shown that endothelial-EVs bind to the scavenger
receptor CD36 on platelets and contribute to thrombosis in
mice (25).
Increased levels of particular EV subtypes have been asso
ciated with specific diseases, and EV subtypes may serve as
novel biomarkers. The plasma level of CD31+ EVs is associated
with increased risk of cardiovascular death (26). Tissue factor
(CD142)-positive EVs derived from endothelial cells and monocytes in sickle cell disease contribute to thrombin generation
and coagulation (27). In a study of critically ill patients, the ratio
of platelet-EVs to platelet count was associated with mortality,
primarily driven by an inverse relationship between platelet count
and mortality (28). In critically ill burn patients, white blood cell
(WBC)- and granulocyte-EVs at intensive care unit (ICU) admission are associated with subsequent mortality (29).
Using RNA sequencing and global transcriptomic analyses,
here we show that plasma-EVs bias primary monocytes toward
an M1 profile, which leads to generation of a dominant inflammatory response. We also show that whether EVs induce pro- or
anti-inflammatory responses in monocytes depends on their
cell of origin. Finally, we demonstrate that a group of scavenger
receptors were regulated in monocytes stimulated with EVs, and
that RBC-EVs bind monocytes at least in part via the scavenger
receptor CD36. We enrolled a subset of 100 critically ill subjects
from three of the clinical sites participating in the Age of BLood
Evaluation (ABLE) trial and measured a broad array of immune
and coagulation parameters to determine if the age of blood
transfused affected these parameters, and secondarily whether
any of the parameters predicted subsequent mortality (30). We
showed that in addition to cystatin C and tissue plasminogen
activator (TPA), EVs expressing CD66b (granulocyte), CD15
(granulocyte and monocyte), CD11b (adhesion molecule), and
CD62P (activated platelets and endothelial cells) are early pre
dictors of mortality in ICU patients.
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Study Samples

For in vitro experiments Trima filters (discarded byproducts of
platelet apheresis) were used to generate large stocks of stored
peripheral blood mononuclear cells (PBMCs). Fresh blood from
six healthy donors was used for isolation of granulocytes to gen
erate pure granulocyte-EVs. To purify RBC- and platelet-EVs,
RBC units and platelet units were washed by automation and
stored for 21 and 5 days, respectively. All filters and units were
de-identified and acquired from Blood Centers of the Pacific
(BCP). All study protocols were approved by the University of
California, San Francisco Committees on Human Research.
Samples from the ABLE study were used for ex vivo experiments. ABLE was a multicenter, randomized, controlled clinical
trial that studied the effect of RBC unit storage time in 1,430
critically ill patients who received RBC transfusion. PBMC samples from a subset of 100 patients in the ABLE trial were collected
pre-transfusion and on days 2, 6, 28, and 180 post-transfusion.
ABLE sites participating in this study included The Ottawa
Hospital (General and Civic campuses) and the Institut de Car
diologie et de Pneumologie de Québec, Université Laval. All
patients from the ABLE trial were eligible to participate, with the
exception of those with history of bone marrow transplantation.
Plasma samples were used for measurement of EVs, cytokines,
growth factors, and coagulation factors. In addition, clinical
data were collected in the ABLE trial, including mortality and
multiorgan dysfunction syndrome score. Samples were collected
under informed consent and IRB approval in accordance with
the Declaration of Helsinki. A group of 48 healthy control subjects
was enrolled at Blood Systems Research Institute, with a blood
sample collected at a single time point for analysis of EV subtypes
in peripheral blood.

Sample Processing

Plasma-EVs were isolated from ACD-treated blood using diff
erential centrifugation. Plasma was separated at 1,000 g from
cells and spun at 13,000 g to make platelet-free plasma (PFP). Six
mL of PFP were added to 30 mL phosphate-buffered saline and
spun for 1 h at 100,000 g. EV pellets were resuspended in 1 mL
RPMI and stored at −80°C. Purified EVs were used for functional
experiments.
For measurement of EV subtypes in peripheral blood, whole
blood from 48 donors was collected in a citrate tube. Tubes were
centrifuged at 2,500 g, and plasma was stored in 0.5 mL aliquots
at −80°C until testing. Whole blood was collected in EDTA tubes
from ABLE study subjects on day 0 (before transfusion) and on
days 2, 6, and 28 after the first RBC transfusion. Collection tubes
were centrifuged at 1,000 g to separate cells from plasma, and
plasma was centrifuged at 13,000 g for removal of platelets and
large fragments of cells. Aliquots of 0.5 mL PFP were stored at
−80°C until testing.

Generation of Pure EV Subtypes Based on
Their Cell of Origin

Pure RBC-, platelet-, monocyte-, granulocyte-, and endothelialEVs were prepared for functional experiments. Monocytes were
2
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isolated from PBMCs of healthy donors by double negative sele
ction using an EasySep Human Monocyte Enrichment Without
CD16 Depletion Kit (Stemcell Technologies), and they were
cultured at 1 million cells/mL for 2 days to generate monocyteEVs in the culture supernatant. Whole blood was treated with
HetaSep (Stemcell Technologies) to sediment RBCs and isolate
leukocytes. Granulocytes were isolated from leukocytes by double
negative selection using an EasySep Human Pan-Granulocyte
Isolation Kit (Stemcell Technologies) and were cultured at 1
million cells/mL for 24 h to generate granulocyte-EVs. Washed
leukoreduced RBC units were stored for 21 days in CP2D plus
AS3 storage solution at 4°C to generate pure RBC-EVs. Platelet
units were washed and stored for 5 days on a shaker at 25°C to
generate platelet-EVs. Human umbilical vein endothelial cells
(University of California, San Francisco Cell Culture Facility) were
cultured to 90% confluence for 1 week to generate endothelialEVs. EV subtypes were isolated from monocyte, granulocyte, and
endothelial cell culture supernatants, and from stored RBC units
and stored platelets by differential centrifugation as described
earlier, followed by storage at −80°C.

double negative selection from PBMCs using the EasySep Human
Monocyte Enrichment Without CD16 Depletion Kit (Stemcell
Technologies).

Stimulation of Monocytes With EVs

Extracellular vesicles were counted using Trucount Absolute
Counting Tubes (BD Biosciences). To each Trucount™ tube, 50 µL
sample and 350 µL PBS were added and samples were read immediately on the flow cytometer. EV concentrations were calculated
using the following equation:
EVs/µL = EV region events / bead region events 
× Trucount beads / µL of sample added .
One million monocytes were cultured in 1 mL of 10% inactivated exosome-free FBS (SBI) in RPMI (containing 10 mM
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 100 U/mL
penicillin G, and 100 mg/mL streptomycin) in the presence or
absence of one million plasma-EVs in a 5% CO2 incubator at 37°C
for 1, 3, and 24 h. Each experiment was performed in duplicate
wells, and cell culture supernatants (0.3 mL) were harvested for
cytokine assays and cells were added to 0.7 mL QIAzol Lysis
Reagent (Qiagen) for total RNA isolation. For experiments using
individual EV subtypes, 1 million monocytes were cultured with
1 million EVs of a given subtype (RBC-, platelet-, monocyte-,
endothelial-, and granulocyte-EVs) for 24 h, and supernatants
were harvested for cytokine assays. For some experiments EVs were
fractionated by size. Briefly, EVs were centrifuged at 500 g using
0.22 µm Ultrafree MC-GV Centrifugal Filter Units (Millipore) to
separate small and large EVs (enriched for exosomes and MVs,
respectively). The small EVs (<220 nm) were collected in the flow
through, and the large EVs (>220 nm) were recovered from the top
of the filter. Each fraction was incubated with monocytes for 16 h
followed by permeabilization of cells using Cytofix/Cytoperm Kit
(BD Biosciences) and intracellular staining for TNF-α (-V421
labeled, BioLegend).

Characterization of EVs

To characterize EVs from patients, PFP samples were stained
and acquired as previously described (31) using 14 different
fluorochrome-conjugated monoclonal antibodies in three separate panels, including CD235a-FITC, CD62P-APC, CD3-PerCP/
Cy5.5, CD19-Alexa/700, CD28-FITC, CD16-V450, CD62L-APC,
CD11b-PE/Cy7, CD66-PE (BioLegend), CD15-FITC (ExAlpha),
CD152-APC, CD14-APC/Cy7, CD108a-PE, and CD41a-PerCP/
Cy5.5 (BD Biosciences). In normal donor samples CD142-PE
(BioLegend) and CD154-APC (BD Biosciences) were substituted
for CD14 and CD152, respectively. To reduce the background
staining and as the size of small EVs fall below the detection limit
of flow cytometer, stained EVs were diluted in PBS and were
centrifuged for 5 min at 500 g using 0.22 µm Ultrafree MC-GV
Centrifugal Filter Units (Millipore). Flow through (small EVs
and unbound antibodies) was discarded, and stained large EVs
were harvested in PBS from the top of the filter. Data were
acquired using an LSR II flow cytometer (BD Biosciences). FSC/
SSC voltages were set to the highest values that excluded the
majority of background noise (i.e., just below the voltage thre
shold at which event rate surpassed 5 events/s while running
a tube of PBS alone). Typically, this threshold occurred at FSC
and SSC voltages of around 500–600 and 300–350, respectively.
Gates were set using beads sized 100, 200, 240, 500, and 1,000 nm
(Megamix-Plus SSC; BioCytex), and EVs were collected from
the threshold to the 1,000 nm gate based on SSC. Analysis was
performed using FlowJo 7.6.5 software (Tree Star).

Gene Expression Profiling With High
Throughput Sequencing

Total RNA from monocytes, EVs, and PBMC positive controls
was extracted using the miRNeasy Mini Kit (Qiagen) with the
optional on-column DNAse treatment step. RNA was quantified
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies) and integrity was assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies). For RNA-Seq experiments
cDNA was generated using the Illumina TruSeq Stranded mRNA
Library Prep Kit (Illumina Technologies), and 400 ng of total RNA
was used as input. Single-read sequencing was performed using
the Illumina HiSeq 2000 instrument to obtain 30–50 million
single reads of 51 nucleotides. RNA-Seq data were preprocessed by
adaptor trimming and low quality 3′-tail trimming (Phred > 20).
The preprocessed reads were mapped using Tophat to the reference genome hg19. Gene level expression quantification in
FPKM (Fragments Per Kilobase of transcript per Million mapped
reads) was calculated using Cufflinks suite including Cufflinks,
Cuffmerge, Cuffquant, and Cuffnorm. Significant changes in

Isolation of PBMCs and Purification
of Monocytes

Whole blood or leukocytes trapped in TRIMA filters were overlaid on Ficoll-Paque (Sigma-Aldrich) and centrifuged for 30 min
at 600 g. PBMC layers were harvested followed by washing and
cryopreservation in fetal bovine serum (FBS) containing 10%
DMSO. Isolation of monocytes from PBMCs was performed by
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transcript expression were quantified by t-test, which were adju
sted by false discovery rate (FDR < 0.05). Gene annotations and
GO terms were extracted from BioMart using the Bioconductor/
biomaRt package.

experiments PBMCs were incubated with monoclonal antibodies
against CD36, CD163, CD206, TLR1, TLR2, or TLR4 in a 5% CO2
incubator at 37°C for 1 h. PBMCs (500,000) were cultured with
EVs, in a final volume of 0.5 mL for 24 h. PBMCs were stained
with CD14-PerCP/Cy5.5 (BioLegend) and were fixed in 2% paraformaldehyde solution. PBMCs were subject to flow cytometry,
and percent binding of monocytes to EVs was measured by gating
on CD14+ cells.

Intracellular Cytokine Assays and
TLR Blocking Antibodies

Intracellular staining of monocytes for detection of TNF-α was
performed after stimulation of 1 million/mL monocytes with
EVs as previously described (7). To test the efficacy of anti-TLR
neutralizing antibodies, one million PBMCs were treated with
1 µg/mL TLR1, TLR2, or TLR4 antibodies for 1 h, and then stimulated with TLR agonists (InvivoGen) for 16 h. Synthetic tripal
mitoylated lipopeptide Pam3CysSerLys4 (Pam3CSK4, 20 ng/mL)
was used as a TLR1 and TLR2 agonist, and LPS (5 ng/mL) was used
as a TLR4 agonist. Finally, cells were stained with CD14-APC/
Cy7 antibody (BioLegend) before permeabilization, then washed
and stained for TNF-α, and run on the flow cytometer.

Measurement of Cytokines and
Coagulation Factors

PFP from 100 ABLE study subjects was analyzed for levels of
immune and coagulation markers. To determine the inflammatory and coagulation profile of PFP, a total of 43 different markers
were measured, including 16 coagulation factors: prothrombin
time, partial thromboplastin time, D-dimer concentration,
factor II, factor V, factor VII, factor VIII/40, factor IX/20, factor X, antithrombin III, protein C, fibrinogen concentration,
thrombomodulin, endothelial cell protein C receptor, TPA, and
plasminogen activator inhibitor type-1 (PAI-1). The markers of
coagulation were analyzed on a Stago or Dade Behring-Siemens
device. Coagulation factors Va, VIIIa, VII, as well as antithrombin III,
prothrombin time, partial thromboplastin time, TPA, D-dimer,
and protein C were measured on a Diagnostica Stago™ coagulation analyzer. Concentrations of prothrombin fragments 1 + 2,
soluble thrombomodulin, PAI-1, soluble endothelial protein
C receptor, and cytokines were measured using commercially
available ELISA kits. In addition, 27 cytokines were measured
using Milliplex MAP kit (Millipore): GM-CSF, IL-12p70, IL-17A,
IL-1β, IL-2, IL-21, IL-23, IL-6, IL-7, IL-8, ITAC, MIP-1α, MIP1β, TNF-α, EGF, FGF, IFN-γ, IP-10, VEGF, β2-microglobulin,
cystatin C, myeloperoxidase, PAI-1, PDGF-AB/BB, RANTES,
sICAM-1, and sVCAM–1. A Bio-Plex 200 instrument (Bio-Rad)
was used for cytokines data acquisition.

Measurement of Cytokines in Supernatant
of Monocytes Stimulated With EVs

A Milliplex MAP Kit (Millipore) was used to measure the level
of 13 cytokines and growth factors in culture supernatants
of monocytes stimulated with plasma-EVs (GM-CSF, IFNγ,
IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
and TNF-α). A second Milliplex MAP kit from the same manufacturer was used to measure the level of 12 cytokines in supernatants of monocytes stimulated with EV subtypes (IFNγ, IL-10,
sCD40L, IL-1RA, IL-1α, IL-1β, IL-6, MIP-1α, TNF-α, MIG,
GM-CSF, and TGF-β). A Bio-Plex 200 instrument (Bio-Rad) was
used for data acquisition.

Cell Surface Expression of Scavenger
Receptors and TLRs

Cell surface expression of scavenger receptors CD36, CD163, and
CD206, and cell surface expression of TLR1, TLR2 and TLR4
on monocytes were assessed by staining PBMCs with CD14PerCP/Cy5.5, CD36-PE, CD163-APC, CD206-Alexa Fluor 488,
TLR2-PE, TLR4-APC (BioLegend), and TLR1-FITC (Invivogen)
fluorochrome-conjugated antibodies according to the manufacturers’ instructions. Samples were fixed in 2% paraformaldehyde
solution and were run on the flow cytometer. Percent expression
of scavenger receptors and MFI of TLRs were measured after
gating on CD14+ monocytes.

Data Analysis

Supervised gene analysis was performed on all genes that were
mapped by high throughput sequencing and used in this paper.
FDRs were computed using the Benjamini–Hochberg procedure
to adjust for multiple comparisons in the RNA-Seq data. The heat
maps were generated using standardized Z-scores. GraphPad
Prism v.6 was used for ANOVA and t-test analyses as noted in
the figure legends. The significance of predictors of mortality was
based on Cox regression analyses. The distribution of the data was
analyzed, and for analytes with non-normally distributed data,
values were log-transformed before analysis.

EV–Monocyte Binding Assay

Plasma-EVs, aged RBC-EVs, or EV subtypes were stained with
PKH26 Red Fluorescent Cell Linker Dye (Sigma-Aldrich). EVs
were washed twice with 10% exosome-free FBS in RPMI to quench
the unbound dye. Recombinant annexin V (BD Biosciences) or
functional grade blocking monoclonal antibodies against phosphatidylserine (PS) (Millipore), CD36 (Stemcell Technologies),
CD163, CD206 (BioLegend), TLR1 (Invivogen), TLR2, and TLR4
(BioLegend) were used at multiple concentrations (0.01–2.0 µg/
mL) to block EV–monocyte binding. In some experiments, EVs
were incubated with annexin V or anti-PS antibody. In other
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RESULTS
EV Exposure Initiates an M1 Phenotype
Gene Expression Program

To better understand how EVs affect human immune cells,
we performed transcriptomic analyses using RNA-Seq on
monocytes at baseline and longitudinally after exposure to
EVs derived from PFP. It has been shown that monocytes and
monocyte-derived macrophages internalize EVs, which leads to

4
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CHI3L2, IL7R, IL2RA, PTX3, SLC2A6, BIRC3, SPHK1, TNF,
EDN1, BCL2A1, CCR7, CCL20, IL6, INHBA, PFKFB3, and SLC7A5
(Figure 1A). Three genes were downregulated at 1 and/or 3 h,
including SLC31A2, PSMB9, and PSAM2. Analysis of M2 genes
showed that the majority of M2-biasing genes with significant
changes after EV exposure were downregulated (Figure 1B). We
found that mRNA of 19 genes were downregulated, most notably
at 3 h post EV exposure, including MSR1, CXCR4, CD302, GAS7,
TPST2, CD36, MS4A6A, LTA4H, TLR5, SLC38A6, SLEC10A, LIPA,
MS4A4A, SLCO2B1, LPAR6, TGFBI, ADK, HS3ST1, and HEXB.
Only four M2-associated genes were upregulated, including

their activation (11, 32, 33). Our prior work demonstrated that
monocytes ingest EVs found in stored RBC units (7), therefore
we focused our studies on this population of immune cells. It has
been shown that several genes are expressed differentially during
the process of monocyte polarization to M1 and M2 profiles, and
that the M1 phenotype has pro-inflammatory effects, while the
M2 phenotype possesses anti-inflammatory properties (34). We
analyzed 53 genes that have been described as associated with the
M1 profile and 43 genes associated with the M2 profile (34). From
M1-associated genes, the mRNA of 19 genes were significantly
upregulated at 3 and/or 24 h, including NAMPT, IL15RA, VCAN,

FIGURE 1 | (A) M1 and (B) M2 mRNA expression profile of extracellular vesicle (EV)-exposed monocytes. Monocytes were purified from peripheral blood
mononuclear cells of five healthy donors and were cultured unstimulated or stimulated with plasma-EVs from five other healthy donors for 0, 1, 3, and 24 h.
mRNA expression was determined by RNA-Seq and analyzed longitudinally for a panel of previously described M1 and M2-associated genes. Results for
EV-incubated conditions were normalized to matched, unstimulated conditions at each time point and log2-transformed (*p < 0.05, **p < 0.01, and ***p < 0.001).
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SLC4A7, CD209, CCL23, and HRH1. In summary, exposure of
primary monocytes to EVs from plasma of healthy donors led
to predominant upregulation of M1-associated genes (19 up and
3 down) and downregulation of M2-associated genes (4 up and
19 down), and the different regulation pattern of M1 and M2associated genes was significant (p < 0.0001, Fisher’s exact test).

sequencing. The mRNA expression of 14 interleukins and
interleukin receptors was significantly upregulated at 3 and/
or 24 h (Figure 2A). We next looked at the gene expression of
chemokines and found 24 mRNA transcripts that were detectable. Expression of 17 chemokines changed significantly, with the
majority upregulated at 3 and/or 24 h (Figure 2B). In contrast
to interleukins and chemokines, most interferon transcripts were
not detectable, and of the five that were, none showed significant
changes after EV exposure (Figure 2C).
To determine whether the changes in cytokine mRNA levels
measured after monocyte exposure to EVs translated to changes
in protein levels, the supernatants from the same stimulated
monocytes were tested using a multiplex cytokine assay. The levels

Effector Molecules Induced in Monocytes
Exposed to EVs

The RNA-Seq data were next analyzed to examine expression
of cytokines and growth factors in more detail. From 36 known
interleukins, message for 27 was detectable by high throughput

FIGURE 2 | Expression of cytokines, chemokines, and growth factors. Monocytes were purified from peripheral blood mononuclear cells of five healthy donors
and were cultured unstimulated or stimulated with plasma-EVs from five other healthy donors for 0, 1, 3, and 24 h. Supervised gene analysis was performed, and
significant changes in transcript expression quantified by t-test, which were adjusted by false discovery rate (<0.05). (A) Of the panel of genes for interleukins or
their receptors, expression of 14 was significantly upregulated and of 3 was downregulated at 3 and/or 24 h in monocytes stimulated with EVs compared with
paired unstimulated samples. (B) Of the chemokines and their receptors, expression of 14 was significantly upregulated and of 3 was downregulated at 3 and/or
24 h. (C) mRNA expression of most interferons was not detectable, and of the detectable messages none was significantly different from unstimulated monocytes.
(D) Supernatants were collected from the same cultures used for mRNA expression analysis. Results for stimulated conditions were normalized to unstimulated
data and log2-transformed to show log-fold increase after stimulation (*p < 0.05, **p < 0.01, and ***p < 0.001).
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of nine pro-inflammatory and four anti-inflammatory cytokines
were measured at 0, 1, 3, and 24 h intervals in the supernatant
of monocytes that were unstimulated or incubated with EVs
isolated from normal donor plasma, and values were reported
as a ratio of EV-exposed to unstimulated conditions at each time
point (Figure 2D). Of the cytokines in the panel, mRNA levels
of TNF and IL7 were elevated at 3 and 24 h after EV exposure,
and mRNA from IL1B was elevated at 24 h. Protein levels of all
these analytes were significantly elevated and concordant with the
mRNA expression data, with the exception that IL6 mRNA was
significantly elevated at 3 h while the elevation in IL-6 protein
did not reach significance until 24 h. In addition, there were two
cytokines with elevated protein levels at 3 h (IFN-γ and IL-8) and
seven cytokines or growth factors with elevated protein levels at
24 h that were either not significantly elevated or not detected in
the mRNA analysis (IL-12p70, IFN-γ, IL-8, GM-CSF, IL-10, IL13, and IL-4). Examination of the mRNA and protein expression
data of four representative cytokines revealed similar patterns
between mRNA and protein expression for TNF-α, IL-1β, and
IL-6, while increases in IL-10 were detectable at the protein
but not mRNA expression level (Figure S1 in Supplementary
Material). To determine whether EV-derived mRNA contributed
to the signal in the RNA-Seq experiments, RNA was quantified
in the monocyte preparations as well as separate PBMC, EV, and
blank well conditions. Monocyte and PBMC controls showed
peaks consistent with both small and mRNA species, while
RNA was not detectable in EV preparations (Figures S2A,B in
Supplementary Material). Overall, these data demonstrate that
EVs found in healthy human plasma bias purified monocytes to
a pro-inflammatory, M1 phenotype.

pure granulocyte-, monocyte-, and endothelial-EVs induced the
secretion of several pro-inflammatory cytokines, in contrast to
platelet- and RBC-EVs.

Gene Regulation and Cell Surface
Expression of Scavenger Receptors

The role of scavenger receptors in EV uptake is an area of active
investigation (25, 35, 36). The mRNA expression of 24 scavenger
receptors was measured by RNA-Seq to determine if these receptors are regulated in monocytes after plasma-EV exposure. The
mRNA expression of scavenger receptors SRA-1 (CD204), SRI-1
(CD163), CD280, SRI-2 (CD163L1), SRB-2 (CD36), and SRJ-1 was
downregulated, and the mRNA expression of SRF-1, and CD209
was upregulated compared with the time-matched unstimulated
condition (Figure S3A in Supplementary Material).
Several scavenger receptors were selected for analysis of pro
tein expression and requirement for EV–monocyte binding. It has
been shown that the scavenger receptor CD36 plays a role in thro
mbosis in mice by binding to endothelial-EVs (25). Monocytes
express the scavenger receptor CD163, which binds to hemoglobin and haptoglobin-hemoglobin complex (37). As RBC-EVs
are loaded with hemoglobin (38), we thought CD163 may play a
role in EV binding. The mRNA expression of CD206, a receptor
on monocytes that binds to mannose residues on bacteria (39),
did not change in the RNA-Seq data, so this gene was included
as a control (Figure S3B in Supplementary Material). To validate
the mRNA findings, the cell surface expression of these receptors
was determined. CD36 expression was decreased significantly 3 h
after stimulation of monocytes with plasma-EVs. Expression of
CD163 on the monocyte cell surface was decreased significantly
at 3 and 24 h. Incubation of monocytes with plasma-EVs did not
significantly change surface CD206 expression (Figure S3C in
Supplementary Material). The surface expression of the scavenger
receptors on monocytes was largely consistent with the mRNA
expression data, with decreases seen after incubation with EVs.

EV Cell of Origin Determines Effect
of EVs on Monocytes

To better discriminate which EVs in plasma affect monocyte phe
notype, we tested EVs derived from purified cell populations.
Monocytes were stimulated with smaller EVs (<220 nm, enriched
for exosomes) and larger EVs (>220 nm, enriched for microvesicles) derived from granulocyte- and platelet-EVs for 16 h and
monitored for TNF-α production. While both small and large EV
fractions of granulocyte-EVs led to production of TNF-α, neither
the small nor the large EV fractions of platelet-EVs induced the
production of this pro-inflammatory cytokine (Figure 3A).
To more comprehensively measure EV subtype effects, purified monocytes were stimulated with RBC-, platelet-, monocyte-,
endothelial-, or granulocyte-EVs, and a panel of 12 cytokines was
measured in cell culture supernatants. Granulocyte-EVs were the
most pro-inflammatory, inducing significant increases in monocyte secretion of TNF-α, IL-1β, IL-6, MIP-1α, and GM-CSF
(Figure 3B). Stimulation of monocytes with monocyte-EVs
led to a significant increase in TNF-α, IL-6, and MIP-1α, and
endothelial-EVs induced IL-6 and MIP-1α secretion. Stimulation
of monocytes with platelet-EVs led to a significant increase of TGFβ production. Analysis of all 12 cytokines revealed EV-induced
changes in IL-10 and IL-1RA as well. Stimulation of monocytes
with RBC-EVs did not change the secretion of cytokines that
we measured (Figure 3C). In general, culturing monocytes with

Frontiers in Immunology | www.frontiersin.org

Gene Regulation and Cell Surface
Expression of Toll-Like Receptors

The expression of TLR1, TLR2, and TLR4 mRNA was examined
after exposure to plasma-EVs, as TLRs have been proposed as
potential receptors for EVs (17, 18). The mRNA expression of
TLR1 was downregulated at 3 h and upregulated at 24 h. The
mRNA expression of TLR2 was upregulated at 3 and 24 h time
points. Expression of TLR4 mRNA was downregulated at 3 h
(Figure S3D in Supplementary Material). The surface expression
of the TLR receptors was not concordant with the gene expression data. TLR1 surface expression did not differ after exposure
to plasma-EVs, while TLR2 and TLR4 surface expression
dropped at 3 h after EV exposure (Figure S3E in Supplementary
Material).

Dependence of EV–Monocyte Binding
on Scavenger Receptors and
Toll-Like Receptors

Plasma-EVs were incubated with PBMCs for 24 h with or without
the addition of annexin V or antibodies to phosphatidyl serine or
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several scavenger receptors. Blocking phosphatidyl serine, CD36,
CD163, or CD206 did not affect EV–monocyte binding (Figure 4A).
Similarly, blockade of TLR1, TLR2, or TLR4 had no effect on EV–
monocyte binding (Figure 4B). To ensure that the TLR antibodies
had blocking activity, PBMCs from two subjects were activated with

LPS or Pam3CSK4 and incubated with TLR4 or TLR1/2 antibodies,
respectively. Monocyte TNF-α production was decreased 30–80%
by the TLR antibodies (Figure S4A in Supplementary Material).
In addition to testing the ability of plasma-EVs to bind to
monocytes, EVs derived from packed RBC units stored for

FIGURE 3 | Continued
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FIGURE 3 | Cytokine secretion by monocytes stimulated with subtypes of extracellular vesicles (EVs). Monocytes from peripheral blood mononuclear cells of six
healthy donors were purified by negative selection. Six replicates of red blood cell-, platelet-, monocyte-, endothelial-, and granulocyte-EVs were prepared as described
in the “Materials and Methods” section. Monocytes were cultured unstimulated or incubated with noted EV subtypes for 24 h. (A) Two independent experiments were
run with small (enriched for exosomes) and large (enriched for MVs) fractions of granulocyte- and platelet-EVs, and the percentage of monocytes that produced TNF-α
was measured by intracellular staining. Representative data showing intracellular cytokine staining of monocytes incubated with small and large fractions of
granulocyte- and platelet-EVs. (B) Supernatants were collected at 24 h and were tested using a multiplex cytokine assay for 12 cytokines. Data were analyzed by
ANOVA, and each condition was compared with the control condition using a Dunnett’s post-test. Data are shown for 6 of the 12 cytokines tested. (C) The log10 ratio
of cytokines induced by incubating monocytes with five subtypes of EVs over the control condition is summarized in a heat map for all 12 cytokines (*p < 0.05,
**p < 0.01, and ***p < 0.001).

populations. Flow plots gated on EVs (events <1 μm by forward
and side scatter, Figure 5A) revealed that the RBC marker CD235a
and platelet marker CD41a were found on separate populations,
while the RBC activation marker CD108a was only found on
EVs also positive for CD235a (Figure 5B). Similarly, EVs bearing the granulocyte marker CD66b were a separate population
from those bearing CD62P (P-selectin), while those bearing the
adhesion molecule CD11b were found almost exclusively on the
granulocyte-EVs (Figure 5C). Platelet-EVs were more numerous
than those derived from any other cell type measured, and those
bearing CD142 (tissue factor) were rarely detected (Figure 5D).
To characterize WBC-EVs, various cell lineage and activation
markers were examined (Figure 5E). EVs bearing markers of
T cells (CD3), B cells (CD19), monocyte/NK cells (CD16), and
granulocytes (CD66b) were all detected. The adhesion molecule
CD15 was detected at higher levels than the adhesion molecule
CD62L (L-selectin), though overall there were insignificant
differences in expression of various WBC markers on EVs in
healthy subjects. These data demonstrate that EVs from different
cell subtypes can be distinguished by flow cytometry and that
WBC-EVs are present at low-level in healthy subjects’ plasma.

42 days were examined for their binding capacity to monocytes.
As we previously published, the predominant EV subtype in
these preparations was RBC-derived (7). Incubation of RBC
unit-EVs with annexin V or anti-phosphatidyl serine antibody
before incubation with monocytes significantly reduced binding
to monocytes. Incubation of monocytes with anti-CD36 antibody
also significantly reduced binding to RBC unit-EVs (Figure 4C).
Based on the data that CD36 blockade decreased interaction
of RBC unit- but not plasma-EVs with monocytes, the binding
capacity of, monocyte-, granulocyte-, RBC-, and platelet-EVs
to primary monocytes was tested with or without monoclonal
antibody blockade of scavenger receptor CD36. A representative titration of antibody is shown for purified RBC-EVs and
monocytes (Figure S4B in Supplementary Material). Inhibition
of binding of platelet-, granulocyte-, and monocyte-EVs to
primary monocytes in PBMC cultures was tested, and none
showed significant inhibition after incubation with anti-CD36
antibody. These data show that CD36 is important in the binding
of RBC-EVs to monocytes, but not for EVs derived from platelets,
granulocytes, or monocytes (Figure 4D).

Cellular Origin of EVs in Healthy Subjects

Predictors of Mortality in Critically Ill
Patients

The plasma EV profile in 48 healthy subjects (42% male, median
age 46) was examined using a panel of markers to identify EVs
bearing markers of endothelial cells (CD142, CD62P), platelets
(CD41a, CD62P), RBCs (CD235a, CD108a), and multiple WBC
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FIGURE 4 | Role of scavenger receptors and TLRs in extracellular vesicle (EV)-monocyte binding. Peripheral blood mononuclear cells (PBMCs) (500,000) from 4
healthy donors were cultured unstimulated or incubated with 100 µL of PKH26 labeled EVs derived from plasma of 4 other healthy donors for 24 h. (A) PBMCs
were incubated with EVs alone, or EVs pre-incubated with annexin V (1.0 µg/mL) or anti-phosphatidylserine (PS) antibody (1.0 µg/mL) for 1 h and added to PBMCs,
or PBMCs were pre-incubated for 1 h with other antibodies noted on the x-axis at 1.0 µg/mL and added to PBMCs. After 24 h cells were stained with anti-CD14
and monocyte-EV binding was analyzed. (B) PBMCs were pre-incubated for 1 h with the noted TLR antagonists before incubation with EVs for 24 h as above.
(C) PBMCs were incubated with EVs derived from red blood cell (RBC) units stored for 42 days, and binding inhibitors were added as above. (D) Binding of EVs
derived from four different purified cell types to monocytes was assessed with or without pre-incubation of PBMCs with anti-CD36 antibody. EV binding inhibition
conditions were compared with the EV alone condition by ANOVA with Dunnett’s post-test (A–C) or by t-test (D) (*p < 0.05, **p < 0.01, and ***p < 0.001).

serial samples were collected from 100 subjects randomized to
receive RBC units that had been stored for a shorter or longer
period. These subjects were 95% medical admissions, were 50%
female, and had a median age of 67. These samples were tested
for an array of 16 coagulation, 27 cytokine, 3 immune cell, and 14
EV markers. The ABLE study found no effect of RBC unit storage

Frontiers in Immunology | www.frontiersin.org

age on mortality or other clinical outcomes, and the longitudinal
analysis of the relationship of these markers with RBC unit age
is the subject of a manuscript in preparation. For this study, we
analyzed the 100 subjects in aggregate to determine if immune
or coagulation markers in samples collected at ICU admission,
pre-transfusion predicted subsequent 28-day mortality, which
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FIGURE 5 | Extracellular vesicles (EVs) in healthy controls and as predictors of mortality in intensive care unit patients. (A) Gating strategy for EVs shows detection
of beads sized 100–1,000 nm on the SSC channel in the left panel, and gating of EVs in the right panel. Representative flow cytometry plots for (B) red blood cell
(RBC) and (C) granulocyte markers are shown. (D) Levels of EVs were measured in 48 healthy control subjects using a panel of markers to identify EVs derived from
platelets (CD41a and CD62P), RBCs (CD235a and CD108a), and endothelial cells (CD142). CD41a+ EVs were significantly more abundant than all other populations
(p < 0.0001); all other significant differences are noted on the graph. (E) White blood cell (WBC)-EVs were characterized based on cell of origin (CD3, CD16, CD19,
CD66b) and expression of co-stimulatory (CD28 and CD154), and adhesion molecules (CD62L, CD11b, and CD15). (F) Of 62 parameters measured at baseline in
100 critically ill subjects, the 6 associated with 28-day mortality are shown, including EVs expressing four markers (CD15, CD11b, CD62P, and CD66b) (*p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001).

was 22% in these subjects (Table 1). Elevated levels of six factors upon intensive care unit (ICU) admission were associated
with subsequent mortality: cystatin C, TPA, and EVs bearing the
markers CD15, CD11b, CD62P, or CD66b (Figure 5F).

revealed that monocyte-, granulocyte-, and endothelial-EVs drove
a pro-inflammatory monocyte response, with granulocyte-EVs
inducing the broadest and highest magnitude response. In addition, platelet-EVs were the only population to induce monocyte
production of the anti-inflammatory cytokine TGF-β, and RBCEVs did not regulate cytokines and chemokines that we measured.
The scavenger receptor CD36 is a potential receptor for RBCEVs but not for the other EV subtypes tested. Finally, we showed
that CD66b+ granulocyte-EVs are early predictors of mortality
in ICU patients.

DISCUSSION
In this article, we show that plasma-EVs biased primary monocytes toward an M1 profile and led to secretion of inflammatory
mediators. Inspection of EVs from purified cell populations
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Knowing that plasma-EVs are comprised of a heterogeneous
mix of subtypes derived from distinct cells of origin (40–42), and
to better understand which EVs in plasma bias monocytes to a proinflammatory phenotype, EVs were prepared from purified cell
populations using routine procedures in a blood bank setting
(RBC- and platelet-EVs), or by culturing unstimulated cells (mono
cyte-, granulocyte-, and endothelial-EVs) to avoid the effect of
mitogens on EV cargo (43). Granulocyte-EVs were found to be
the most potent pro-inflammatory agents of the EV subtypes
studied, followed by monocyte- and endothelial-EVs in proinflammatory activity in our in vitro assays. Granulocyte-EVs have
also been described to augment or suppress immune response
(42, 43). Eken et al. have reported that EVs released by granulocytes induce a MerTK-dependent anti-inflammatory pathway
in monocyte-derived macrophages (44). One difference between
that study and the current work is that they stimulated purified
granulocytes with fMLP to generate EVs. This stimulation could
have affected the EV cargo and composition compared with
EVs that are released during physiologic conditions or from
granulocytes that were not stimulated (45). In contrast to the
pro-inflammatory EVs, platelet-EVs induced TGF-β secretion by
monocytes. TGF-β is a multifunctional cytokine with a dominant

immunosuppressive activity. While it plays a positive role in
tissue repair and in the control of autoimmune and infectious
diseases, its upregulation may increase the growth of tumor cells
(46). Platelet-EVs may have therapeutic value in tissue repair and
downregulating the immune system in autoimmune diseases.
After demonstrating that plasma-EVs activated monocytes,
we searched for antibodies that could block EV–monocyte binding. The RNA-Seq data showed the downregulation of a cluster of
scavenger receptors on monocytes followed by their stimulation
with total EVs. Two well-known scavenger receptors that were
downregulated (CD36 and CD163) and one whose gene transcription did not change (CD206) were selected for functional
studies. Blockade of these receptors did not affect the binding of
plasma-EVs to monocytes, though anti-CD36 antibody blocked
RBC-EV binding to monocytes. A prior study has shown that
endothelial-EVs bind to the scavenger receptor CD36 on platelets
and contribute to thrombosis in mice (25). We found that the
scavenger receptors CD36 and CD163 were downregulated
on the cell surface of monocytes stimulated with plasma-EVs;
however, a binding inhibition assay showed that only CD36 was
involved in RBC-EV binding to monocytes. Given the relative
lack of effect of RBC-EVs in our monocyte stimulation assays,

TABLE 1 | Baseline predictors of mortality.
Coagulation

Cytokines

Parameter

p Value

HR (cb)

PT
PTT
D-dimer
Factor II
Factor V
Factor VII
Factor VIII40
Factor IX
Factor X
ATIII
PC
FIB
TM
ECPR
TPA
PAI-1

0.33
0.085
0.7
0.28
0.21
0.28
0.63
0.96
0.95
0.74
0.18
0.26
0.69
0.72
0.011
0.27

1.02 (0.97–1.08)
1.01 (0.999–1.017)
1.04 (0.86–1.25)
0.99 (0.97–1.01)
0.99 (0.98–1.004)
0.75 (0.45–1.26)
1.00 (0.998–1.003)
1.00 (0.99–1.01)
0.99 (0.98–1.01)
1.03 (0.88–1.20)
0.90 (0.78–1.05)
0.99 (0.98–1.01)
1.18 (0.51–2.73)
1.01 (0.94–1.10)
1.57 (1.10–2.22)
1.14 (0.93–1.44)

Extracellular vesicles

Parameter

p Value

HR (cb)

GM-CSF
IFN-γ
IL-10
IL-12p70
IL-17A
IL-1β
IL-2
IL-21
IL-23
IL-6
IL-7
IL-8
ITAC
MIP-1α
MIP-1β
TNF-α
EGF
FGF
VEGF
β2-Microglobulin
Cystatin C
MPO
PDFG AB/BB
RANTES
sICAM-1
sVCAM-1

0.059
0.84
0.84
0.84
0.3
0.89
0.62
0.31
0.84
0.62
0.69
0.62
0.92
0.19
0.24
0.81
0.82
0.82
0.29
0.28
<0.0001
0.26
0.59
0.47
0.57
0.084

0.70 (0.48–1.01)
0.97 (0.73–1.29)
1.03 (0.77–1.37)
1.06 (0.58–1.96)
0.81 (0.54–1.21)
1.06 (0.45–2.49)
0.85 (0.45–1.61)
0.73 (0.40–1.34)
0.98 (0.78–1.22)
0.92 (0.67–1.27)
1.01 (0.94–1.09)
1.10 (0.75–1.61)
0.98 (0.70–1.38)
0.73 (0.46–1.17)
0.70 (0.38–1.26)
1.06 (0.67–1.67)
1.03 (0.77–1.39)
0.97 (0.72–1.30)
1.10 (0.92–1.31)
1.12 (0.91–1.31)
1.04 (1.02–1.07)
1.19 (0.88–1.59)
1.05 (0.88–1.26)
0.91 (0.70–1.18)
1.01 (0.98–1.04)
1.02 (1.00–1.04)

Parameter

p Value

HR (cb)

EV concentration
Annexin V
CD3
CD14
CD16
CD19
CD28
CD152
CD41a
CD62L
CD108a
CD235a
CD11b
CD15
CD62P
CD66b

0.83
0.85
0.78
0.56
0.62
0.8
0.22
0.59
0.32
0.091
0.71
0.98
0.01
0.021
0.008
0.001

1.04 (0.74–1.45)
0.98 (0.80–1.20)
1.04 (0.79–1.37)
1.06 (0.88–1.27)
0.93 (0.70–1.24)
0.97 (0.76–1.24)
1.11 (0.94–1.31)
0.93 (0.72–1.21)
1.12 (0.89–1.41)
1.22 (0.97–1.55)
0.94 (0.70–1.28)
1.00 (0.76–1.31)
1.44 (1.09–1.91)
1.25 (1.03–1.52)
1.34 (1.08–1.66)
1.60 (1.20–2.15)

Cellular immunity
Treg
CD4-IL-7
CD8-IFN-γ

0.098
0.21
0.3

1.25 (0.96–1.63)
2.30 (0.63–8.37)
0.98 (0.94–1.02)

HR, hazard ratio; cb, confidence bound; PAI-1, plasminogen activator inhibitor type-1; TPA, tissue plasminogen activator; EV, extracellular vesicle.
Significant values in bold.
HRs reflect the change in the hazard that is associated with one unit of change in particular variables except as noted below.
10 units of change: GM-CSF, IFN-γ, IL-10, IL-23, IL-6, IL-8, ITAC, EGF, FGF, and VEGF.
100 units of change: PDFG AA/BB, CD3, CD14, CD16, CD19, CD28, CD152, CD62L, CD108a, CD11b, CD15, and CD66b.
1,000 units of change: RANTES, CD235a, CD62P, and annexin V.
10,000 units of change: MPO, sICAM-1, CD41a, and EV concentration.
1 million units of change: cystatin C.
10 million units of change: β2-microglobulin.
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it is unclear how effective CD36 blockade would be in regulating immune changes potentially induced by transfusions rich in
RBC-EVs, though other investigators have described RBC-EVs
as having immune suppressive activity (9). Blockade of CD9,
CD81, CD54, CD11a, CD51, and CD61 is reported to reduce EV
uptake by dendritic cells (22). The interaction of lectin family
members such as CD205 and CD209 has also been studied, and
their blockade leads to reduced EV uptake (21, 23). In general, EV
uptake cannot be prevented completely by blockade of one receptor, suggesting that several receptors are involved (12, 19, 21–24).
TLRs have also been described to play a role in EV uptake. We
tested antibodies against TLR1, TLR2, and TLR4, and they did
not block EV–monocyte binding. It has been shown that tumorexosomes control the expansion of myeloid-derived suppressor
cells through TLR2 and not TLR4, which leads to secretion of
IL-6 and suppression of CD8+ T cells (18). However, it was found
in another study that stimulation of the monocytic cell line THP1
with tumor-exosomes induced TNF-α, IL-1β, and IL-6 through
TLR2 and TLR4 signaling (17).
In our ex vivo study on plasma samples from ICU patients,
a panel of 43 cytokines and coagulation factors was examined,
and only TPA and cystatin C were associated with mortality risk
(47–52). TPA is involved with fibrinolysis and has been reported to
be a marker for subsequent mortality in subjects hospitalized for
acute dyspnea (50). Its significant release by endothelial cells after
traumatic injury has been shown to result in excessive bleeding
and hyperfibrinolysis, which are known risk factors for mortality
(48, 49). Cystatin C is a cysteine protease inhibitor that plays a
role in catabolism of proteins, and it has been widely described
as being associated with mortality risk in various disease states
(47, 51, 52). In addition, 4 of the 14 EV markers tested were associated with increased death risk in this population of critically

ill patients who primarily presented with medical as opposed to
surgical diagnoses (30). The existing literature is relatively scarce
describing the prognostic potential of EVs as predictors of mortality. Our results indicate that CD66b, CD15, CD11b, and CD62P
EVs were predictors of mortality in our cohort of patients. Of
these, CD66b is the most specific and is a marker for granulocytes
(53). CD15 is expressed on granulocytes and monocytes (54),
and given that levels of the monocyte markers CD14 and CD16
were not associated with risk of death, it is likely that the CD15
EVs arose from granulocytes rather than monocytes. CD11b is
expressed on many cell types including granulocytes, monocytes,
and lymphocytes (55), so while elevated CD11b-expressing EVs
is consistent with a granulocyte cell of origin, this marker is not
specific. CD62P is an endothelial and platelet marker (56), and
in this study EVs bearing the platelet marker CD41a were not
associated with mortality risk. CD41a-expressing EVs have been
reported to be positively or negatively associated with mortality
in prior studies (57–59). Endothelial-EV markers were not mea
sured in this study, though it is possible that CD62P EVs were
derived from endothelial cells. The upregulation of endothelialEVs has been described in patients with systemic inflammation
due to sickle cell disease (27). Given the exploratory nature of
the large panel of analytes studied, correlations were not corre
cted for multiple comparisons. The pattern of predominantly
granulocyte-EVs correlating with mortality risk is suggestive
that the correlations were not random, though future studies
will be needed to confirm the association. Of note, WBC- and
granulocyte-EVs were recently reported to be associated with
subsequent mortality in a population of critically ill burn patients,
increasing confidence in the validity of the association (29). Our
data are consistent with a model in which EVs from various cell
types signal circulating monocytes, which can synthesize these

FIGURE 6 | Hypothetical model of extracellular vesicle (EV) interaction with monocytes. In this model, acute infection results in augmented release of EVs from cells,
particularly granulocytes, which are ingested by monocytes. Activated monocytes can then differentiate and migrate to tissues, which can increase tissue
inflammation and damage. Abbreviations: PMN, polymorphonuclear cell (granulocyte); Plt, platelet.
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